Marshall Wace LLP Invests $1.55 Million in Solid Biosciences Inc. (NASDAQ:SLDB)

Marshall Wace LLP purchased a new stake in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 274,005 shares of the company's stock, valued at approximately $1,554,000. Marshall Wace LLP owned approximately 0.71% of Solid Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Solid Biosciences by 283.9% in the first quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company's stock worth $16,578,000 after purchasing an additional 920,404 shares during the period. Janus Henderson Group PLC bought a new position in Solid Biosciences in the 1st quarter worth about $23,935,000. Acadian Asset Management LLC purchased a new stake in shares of Solid Biosciences in the 2nd quarter valued at about $379,000. Bank of New York Mellon Corp purchased a new position in shares of Solid Biosciences during the second quarter worth about $392,000. Finally, American Century Companies Inc. increased its position in shares of Solid Biosciences by 39.9% in the second quarter. American Century Companies Inc. now owns 34,557 shares of the company's stock worth $196,000 after purchasing an additional 9,853 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Price Performance

SLDB traded down $0.12 during trading on Friday, hitting $6.58. 179,128 shares of the stock traded hands, compared to its average volume of 210,027. The firm has a market capitalization of $253.99 million, a P/E ratio of -1.67 and a beta of 1.90. Solid Biosciences Inc. has a 12-month low of $1.81 and a 12-month high of $15.05. The firm has a 50-day moving average of $8.12 and a 200 day moving average of $8.69.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.05. As a group, equities analysts predict that Solid Biosciences Inc. will post -2.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Leerink Partnrs raised shares of Solid Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 24th. Barclays cut their target price on shares of Solid Biosciences from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Wednesday, August 14th. Leerink Partners raised Solid Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 target price on the stock in a research note on Monday, June 24th. William Blair raised Solid Biosciences to a "strong-buy" rating in a research note on Friday, August 30th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a research report on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Solid Biosciences has an average rating of "Buy" and a consensus price target of $15.67.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.